ALXO [NASD]
ALX Oncology Holdings Inc.
Index- P/E- EPS (ttm)-2.32 Insider Own2.10% Shs Outstand40.62M Perf Week0.70%
Market Cap327.46M Forward P/E- EPS next Y-3.43 Insider Trans-46.07% Shs Float25.40M Perf Month-44.47%
Income-93.80M PEG- EPS next Q-0.69 Inst Own91.70% Short Float14.47% Perf Quarter-43.12%
Sales0.00M P/S- EPS this Y24.90% Inst Trans1.19% Short Ratio9.69 Perf Half Y-80.74%
Book/sh8.46 P/B1.02 EPS next Y-33.50% ROA-24.00% Target Price48.38 Perf Year-84.44%
Cash/sh8.35 P/C1.03 EPS next 5Y- ROE-25.10% 52W Range8.31 - 81.19 Perf YTD-59.80%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-89.36% Beta-
Dividend %- Quick Ratio21.00 Sales past 5Y- Gross Margin- 52W Low3.97% ATR1.26
Employees44 Current Ratio21.00 Sales Q/Q- Oper. Margin- RSI (14)29.53 Volatility10.69% 11.40%
OptionableYes Debt/Eq0.00 EPS Q/Q-70.60% Profit Margin- Rel Volume0.91 Prev Close9.75
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume379.49K Price8.64
Recom2.00 SMA20-27.78% SMA50-44.13% SMA200-76.27% Volume344,903 Change-11.38%
Dec-22-21Downgrade Jefferies Buy → Hold $65 → $25
Sep-30-21Initiated Stifel Buy $106
May-05-21Resumed Credit Suisse Outperform $98
Apr-26-21Resumed Credit Suisse Outperform $98
Apr-06-21Initiated UBS Buy
Feb-10-21Initiated H.C. Wainwright Buy $100
Aug-11-20Initiated Piper Sandler Overweight $55
Aug-11-20Initiated Jefferies Buy $50
Aug-11-20Initiated Credit Suisse Outperform $53
Aug-11-20Initiated Cantor Fitzgerald Overweight $64
Apr-12-22 07:00AM  
Mar-02-22 07:00AM  
Feb-28-22 07:00AM  
Feb-03-22 07:01PM  
Feb-02-22 01:38PM  
Jan-28-22 12:44PM  
08:02AM  
Jan-27-22 05:51PM  
Jan-19-22 06:23AM  
Jan-10-22 06:00AM  
Jan-04-22 07:00AM  
Dec-14-21 09:00AM  
Dec-13-21 01:58PM  
Dec-12-21 09:00AM  
Nov-11-21 04:05PM  
Nov-09-21 11:13AM  
07:00AM  
Nov-04-21 09:00AM  
Nov-02-21 09:00AM  
Oct-21-21 11:19AM  
07:00AM  
Oct-07-21 07:00AM  
Oct-01-21 08:00AM  
Sep-16-21 07:00AM  
Sep-14-21 07:00AM  
Sep-07-21 07:00AM  
Aug-27-21 06:55AM  
Aug-12-21 04:05PM  
Jul-28-21 07:00AM  
Jul-15-21 12:00PM  
01:36AM  
Jul-12-21 06:07AM  
Jul-06-21 09:15AM  
Jul-03-21 07:15AM  
Jun-14-21 07:00AM  
Jun-10-21 07:00AM  
May-18-21 07:00AM  
May-17-21 04:05PM  
May-10-21 07:00AM  
Apr-21-21 04:05PM  
Apr-16-21 01:41AM  
Apr-05-21 07:00AM  
Mar-18-21 04:05PM  
Mar-15-21 07:00AM  
Mar-05-21 08:15AM  
Mar-04-21 04:05PM  
Mar-03-21 08:34AM  
Mar-02-21 07:00AM  
Feb-10-21 10:05AM  
Jan-16-21 01:12AM  
Jan-11-21 07:00AM  
Jan-05-21 07:00AM  
Dec-17-20 07:00AM  
Dec-14-20 04:05PM  
Dec-11-20 10:55PM  
Dec-09-20 10:26PM  
Dec-07-20 04:08PM  
10:00AM  
07:00AM  
Nov-24-20 07:00AM  
Nov-12-20 04:05PM  
Nov-09-20 08:10AM  
Nov-05-20 07:00AM  
Nov-02-20 07:00AM  
Oct-28-20 07:00AM  
Oct-14-20 04:25PM  
Oct-06-20 07:00AM  
Sep-22-20 07:00AM  
Sep-17-20 07:00AM  
Sep-08-20 07:00AM  
Aug-27-20 04:05PM  
Jul-21-20 04:05PM  
Jul-17-20 04:17PM  
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GARCIA PETER SChief Financial OfficerFeb 07Option Exercise4.4915,00067,30524,483Feb 08 08:23 PM
Pons JaumePresident & CEOFeb 03Option Exercise1.4624,15435,186468,978Feb 07 08:27 AM
Randolph SophiaChief Medical OfficerDec 15Option Exercise1.4223,85233,788188,396Dec 16 08:47 PM
Lettmann JasonDirectorDec 13Sale27.36325,3778,901,804285,956Dec 15 09:48 PM
LSV Associates, LLC10% OwnerDec 13Sale26.6148,3901,287,431285,956Dec 15 09:03 PM
Lettmann JasonDirectorDec 10Sale31.3126,274822,719291,758Dec 10 09:22 PM
LSV Associates, LLC10% OwnerDec 10Sale31.3126,274822,719291,758Dec 10 07:51 PM
LSV Associates, LLC10% OwnerDec 09Sale32.0376,9052,463,502294,909Dec 10 07:51 PM
Lettmann JasonDirectorDec 09Sale32.0376,9052,463,502294,909Dec 10 09:22 PM
Lettmann JasonDirectorDec 08Sale33.2542,4581,411,871304,131Dec 10 09:22 PM
LSV Associates, LLC10% OwnerDec 08Sale33.2542,4581,411,871304,131Dec 10 07:51 PM
Randolph SophiaChief Medical OfficerNov 22Option Exercise4.0830,000122,400179,428Nov 23 04:29 PM
Randolph SophiaChief Medical OfficerNov 22Sale36.7714,884547,314164,544Nov 23 04:29 PM
Pons JaumePresident & CEOOct 19Sale54.2916,700906,714444,598Oct 20 07:10 PM
Pons JaumePresident & CEOOct 19Sale54.2916,700906,714444,598Oct 20 07:09 PM
GARCIA PETER SChief Financial OfficerOct 18Option Exercise4.087,22929,49416,560Oct 19 04:28 PM
GARCIA PETER SChief Financial OfficerOct 18Sale55.447,229400,7939,331Oct 19 04:28 PM
Randolph SophiaChief Medical OfficerOct 11Sale60.977,387450,422149,428Oct 12 04:29 PM
Pons JaumePresident & CEOSep 20Sale74.3816,7001,242,213461,298Sep 21 04:17 PM
GARCIA PETER SChief Financial OfficerSep 17Option Exercise4.0811,34546,28820,676Sep 17 08:45 PM
GARCIA PETER SChief Financial OfficerSep 17Sale78.9611,345895,8119,331Sep 17 08:45 PM
GARCIA PETER SChief Financial OfficerSep 16Option Exercise4.081,4265,81810,757Sep 17 08:45 PM
GARCIA PETER SChief Financial OfficerSep 16Sale80.431,426114,6959,331Sep 17 08:45 PM
Randolph SophiaChief Medical OfficerSep 10Sale77.667,387573,670156,815Sep 13 07:10 PM
GARCIA PETER SChief Financial OfficerAug 23Option Exercise4.0860,000244,80069,331Aug 24 06:17 PM
GARCIA PETER SChief Financial OfficerAug 23Sale74.1560,0004,448,7629,331Aug 24 06:17 PM
Pons JaumePresident & CEOAug 19Sale61.2816,7001,023,340477,998Aug 20 08:07 PM
GARCIA PETER SChief Financial OfficerAug 17Option Exercise4.0810,00040,80019,331Aug 18 07:11 PM
GARCIA PETER SChief Financial OfficerAug 17Sale66.2310,000662,2999,331Aug 18 07:11 PM
Randolph SophiaChief Medical OfficerAug 10Sale64.637,387477,439164,202Aug 11 04:11 PM
Pons JaumePresident & CEOJul 19Sale54.5716,700911,245494,546Jul 20 04:12 PM
Randolph SophiaChief Medical OfficerJul 12Sale54.907,387405,527171,589Jul 14 04:50 PM
Pons JaumePresident & CEOJun 21Sale58.5916,700978,480511,246Jun 22 04:26 PM
Randolph SophiaChief Medical OfficerJun 10Sale60.887,387449,697178,976Jun 14 04:08 PM